Table 3 Clinicopathological features of mucoepidermoid carcinomas with CRTC3–MAML 2, CRTC1–MAML2, and no detectable gene fusion
From: Clinicopathological significance of the CRTC3–MAML2 fusion transcript in mucoepidermoid carcinoma
Factor | MAML2 fusion partner | P | ||||
|---|---|---|---|---|---|---|
CRTC3 (n=6) | CRTC1 (n=34) | None (n=61) | CRTC3 vs CRTC1 | CRTC3 vs none | CRTC1 vs none | |
Age (years) | ||||||
Mean | 36 | 55 | 58 | 0.01 | 0.0006 | N.S. |
Sex | ||||||
Male | 2 | 15 | 38 | N.S. | N.S. | N.S. |
Female | 4 | 19 | 23 | |||
Tumor site | ||||||
Major | 3 | 15 | 20 | N.S. | N.S. | N.S. |
Minor | 3 | 19 | 41 | |||
Tumor size | ||||||
<2 cm | 2 | 15 | 16 | N.S. | N.S. | 0.007 |
>2 cm | 4 | 19 | 45 | |||
Nodal status | ||||||
Positive | 0 | 2 | 24 | N.S. | 0.08 | 0.0003 |
Negative | 6 | 32 | 37 | |||
Clinical stage | ||||||
I or II | 6 | 31 | 34 | N.S. | 0.07 | 0.0004 |
III or IV | 0 | 3 | 27 | |||
Histological grade | ||||||
Low+intermediate | 6 | 34 | 37 | N.S. | 0.08 | <0.0001 |
High | 0 | 0 | 24 | |||
